Literature DB >> 25253372

Depression and anxiety disorders among gastroenterologic outpatients.

Ilker Tasci1, Umut Safer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253372      PMCID: PMC4196354          DOI: 10.4103/1319-3767.141702

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


× No keyword cloud information.
Sir, Studies have shown that subjects with depression have altered secretion of ghrelin, a well-characterized, appetite-stimulating hormone produced in gastrointestinal system. Although blood ghrelin response is diminished after meal in untreated subjects with depression, it increases after appropriate antidepressive treatment.[12] Moreover, gastrointestinal hormones, including leptin and ghrelin, also have systemic effects, and their metabolism is altered in certain gastrointestinal system disorders.[3] Therefore, through even this single view, successful treatment of patients with depression seems to be required to increase long-term wellbeing. Recently, Alosaimi et al. reported that depression and anxiety were quite common in gastroenterologic outpatients, especially in those who had a chronic course of multiple gastrointestinal complaints.[4] Like some other previous reports, this study once more suggested the necessity of collaborations between gastroenterologists and psychiatrists. Otherwise, the clinicians will continue with acid-blocking agents and others that are now recognized for significant side effects when taken for long periods.[5] On the other hand, in the routine, psychiatrists are prone to guide treatment response to antidepressants using mainly behavioral changes. Therefore, patient-based contact with a psychiatrist may improve management of gastrointestinal symptoms in the outpatient setting. Moreover, in future, gastroenterologists might add depression medications to their own practice to increase patient comfort and reduce the time of acid blocker use. However, we are also yet unsure whether selective serotonin reuptake inhibitors that are used widely to treat depression is safe for the gastrointestinal system,[6] or older but still used H2-receptor antagonists can cause central nervous system symptoms (mental confusion, headache, and depression).[7]
  7 in total

Review 1.  Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?

Authors:  Yuhong Yuan; Keith Tsoi; Richard H Hunt
Journal:  Am J Med       Date:  2006-09       Impact factor: 4.965

Review 2.  Clinically important adverse effects and drug interactions with H2-receptor antagonists: an update.

Authors:  M J Sax
Journal:  Pharmacotherapy       Date:  1987       Impact factor: 4.705

3.  Unstimulated and glucose-stimulated ghrelin in depressed patients and controls.

Authors:  Georgios Paslakis; Sabine Westphal; Bettina Hamann; Maria Gilles; Florian Lederbogen; Michael Deuschle
Journal:  J Psychopharmacol       Date:  2014-03-26       Impact factor: 4.153

Review 4.  FDA drug safety communications: a narrative review and clinical considerations for older adults.

Authors:  Zachary A Marcum; Joseph P Vande Griend; Sunny A Linnebur
Journal:  Am J Geriatr Pharmacother       Date:  2012-06-08

5.  Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity.

Authors:  Murat Pinar; Murat Gulsun; Ilker Tasci; Ahmet Erdil; Erol Bolu; Cengizhan Acikel; Ali Doruk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-08       Impact factor: 5.067

Review 6.  Helicobacter pylori infection and its relationship to metabolic syndrome: is it a myth or fact?

Authors:  Waleed I Albaker
Journal:  Saudi J Gastroenterol       Date:  2011 May-Jun       Impact factor: 2.485

7.  Association of help-seeking behavior with depression and anxiety disorders among gastroenterological patients in Saudi Arabia.

Authors:  Fahad D Alosaimi; Omar Al-Sultan; Qusay Alghamdi; Ibrahim Almohaimeed; Sulaiman Alqannas
Journal:  Saudi J Gastroenterol       Date:  2014 Jul-Aug       Impact factor: 2.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.